Redusta, Efrin, SR.. D.
HRN: 03-14-97 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/28/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
10/28/2022
11/04/2022
IV
500 Mg
Q8H
AGE With Moderate Dehydration
Waiting Final Action
Indication: Empiric Type of Infection: Intra-abdominal Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes